A phase II study of photodynamic therapy (PDT) with aminolevulinic acid HCl (ALA) 20% topical solution + blue light vs ALA topical solution vehicle + blue light using spot and broad area application and incubation times of 1, 2 and 3 hours for the treatment - 13/02/13
Doi : 10.1016/j.jaad.2012.12.648
Le texte complet de cet article est disponible en PDF.
David Pariser, MD, Virginia Clinical Research, Inc, Norfolk, VA, United States; Diane McConnehey, DO, Northwest Clinical Trials, Inc, Boise, ID, United States; Michael Bukhalo, MD, Altman Dermatology Associates, Arlington Heights, IL, United States; Robert Matheson, MD, Oregon Medical Research Center, PC, Portland, OR, United States; Scott Guenthner, MD, The Indiana Clinical Trials Center, PC, Plainfield, IN, United States; Steven Kempers, MD, Minnesota Clinical Study Center, Fridley, MN, United States
Le texte complet de cet article est disponible en PDF.| This poster describes the results of a multicenter clinical trial sponsored by DUSA Pharmaceuticals, Inc. |
© 2013
Publié par Elsevier Masson SAS.
Vol 68 - N° 4S1
P. AB156 - avril 2013 Retour au numéro
Article précédent
- A phase II study of photodynamic therapy (PDT) with aminolevulinic acid HCl (ALA) 20% topical solution + blue light versus aminolevulinic acid HCl topical solution vehicle (VEH) + blue light for the treatment of actinic keratoses (AKs) on the upper extremi
- Abrikossoff tumor of the heel: A case report
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?